Resources
Indication and Important Safety Information
Indication
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Important Safety Information
In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).
For more information about VILTEPSO, see full Prescribing Information.
Get Started
NS Support Patient Consent Form
Following a prescription from your doctor, fill out this form to give your doctor permission to share your medical information with NS Support.
VILTEPSO Start Form
Work with your doctor to complete the VILTEPSO start form and enroll into the NS Support program.
Guides & Brochures
VILTEPSO Overview Brochure
Medicaid Fair Hearing Brochure
More Resources
Learn More About VILTEPSO
Explore this FDA-approved exon 53-skipping therapy for Duchenne muscular dystrophy.
Have Questions?
Call 1-833-NSSUPRT (1‑833‑677‑8778)
Monday–Friday, 8 AM–8 PM ET.
Reach out via email